Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thyrotropin suppression by metformin.

Robert A Vigersky1, Amy Filmore-Nassar, Allan R Glass

  • 1Endocrinology Service, Walter Reed, Army Medical Center, Washington, DC 20307, USA. robert.vigersky@na.amedd.army.mil

The Journal of Clinical Endocrinology and Metabolism
|October 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glycemic Concordance of Simplera Sync<b>™</b> and Instinct<b>™</b> Sensors in MiniMed<b>™</b> 780G System Users: A Randomized Crossover Feasibility Study.

Diabetes technology & therapeutics·2026
Same author

Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes.

Diabetes technology & therapeutics·2026
Same author

MiniMed<sup><b>™</b></sup> 780G System Users Achieve Similar Glycemic Outcomes Regardless of Socioeconomic Disadvantage.

Diabetes technology & therapeutics·2026
Same author

Automated insulin delivery with the MiniMed™ 780G system reduces burden by improving sleep and glycaemic control overnight.

Diabetes, obesity & metabolism·2026
Same author

MiniMed 780G Advanced Hybrid Closed-Loop System Use During Days Without User-Initiated Boluses.

Diabetes care·2026
Same author

Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial.

Frontiers in endocrinology·2026

Metformin use in hypothyroid patients suppressed thyroid-stimulating hormone (TSH) levels without causing hyperthyroidism. This effect may offer new therapeutic options for thyroid cancer patients.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Internal Medicine

Background:

  • Drug-induced alterations in thyroid hormone economy are not well-documented.
  • Metformin, a widely used antidiabetic drug, has not been previously reported to affect thyroid hormone levels.
  • Understanding potential drug interactions is crucial for patient safety and effective treatment.

Observation:

  • This study observed four patients with chronic hypothyroidism on stable levothyroxine (L-T4) therapy.
  • Metformin was initiated in these patients for conditions including diabetes mellitus and nonalcoholic steatohepatitis.
  • Thyroid hormone levels were monitored after metformin initiation.

Findings:

  • Initiation of metformin led to suppressed serum TSH levels in all four patients.

Related Experiment Videos

  • TSH suppression occurred without clinical or biochemical evidence of hyperthyroidism.
  • Free T4 and free T3 levels remained unchanged in the observed patients.

    • Implications:

    • The mechanism behind metformin-induced TSH suppression is currently unknown.
    • Further prospective studies are needed to confirm these findings.
    • Metformin's TSH-suppressing effect could potentially be beneficial as an adjunct therapy for thyroid cancer patients.